Hints and tips:
Related Special Reports
...Investor excitement about Zealand comes as pharma groups seek to follow Novo Nordisk and Eli Lilly into the lucrative obesity market....
...Kasim Kutay, Novo Holdings chief executive and a Novo Nordisk board member, told the Financial Times that rising income from its 28 per cent stake in Novo Nordisk and other investments would give his fund...
...He said Novo Nordisk was facing a “similar challenge” as some of the companies selling advanced therapies....
...But she said if Novo Nordisk could develop such a treatment, it would be “ideal”....
...Lars Fruergaard Jørgensen, chief executive of Novo Nordisk, Europe’s largest pharma group by market capitalisation, was paid DKr68mn (£7.8mn) last year....
...However, the plants will not enable Novo Nordisk to ramp up production until 2026....
...Ozempic” takes, referring to the diabetes and obesity medicine produced by Eli Lilly’s rival in the category, Novo Nordisk....
...Developed respectively by Novo Nordisk and Eli Lilly, they are now being prescribed to millions of people....
...As part of the transaction, Novo Holdings, which controls the majority of the Danish pharma group’s voting rights, has agreed to sell three of Catalent’s manufacturing sites to Novo Nordisk....
...Novo Nordisk shares hit a record high on Wednesday, as the Danish pharma group’s blockbuster weight-loss drugs powered a surge in sales and profits last year, cementing its position as Europe’s most valuable...
...Like Novo Nordisk’s Wegovy and Ozempic, Viking’s VK2735 mimics the GLP-1 hormone that can suppress appetite....
...In the past year, Novo Nordisk has become Europe’s largest company by market capitalisation, while Eli Lilly overtook Johnson & Johnson as the world’s most valuable pharma company, on the back of high demand...
...Novo Nordisk’s blockbuster offering Wegovy is expected to be approved for sale in China this year. That would be another boost for the Danish company....
...The deals come as investor interest in weight-loss drugs grows and pharma groups seek new treatments....
...Novo Nordisk’s trial studied more than 17,600 people aged above 45 with obesity who had cardiovascular disease, but not diabetes....
...Not only are other pharma groups scrambling to buy up biotechs with promising obesity drugs, but Eli Lilly and Novo Nordisk also are putting the drugs to work on other disease areas....
...“That’s actually a fairly good frame of mind to have if you work in the pharma industry.” Novo Nordisk could invest for the very long term partly because of its unusual ownership structure....
...But while Rolls-Royce may have trounced Novo Nordisk in annual share price gains, the pharma giant — riding high on its drugs for obesity — retains bragging rights when it comes to size....
...A month later, Novo Nordisk struck two deals. It bought Montreal-based Inversago Pharma for up to $1.1bn, despite it having just 22 employees....
...Innovation is moving to the US,” Lars Fruergaard Jørgensen, president of Efpia and chief executive of Novo Nordisk, the EU’s most valuable drugmaker, told the FT....
...Take Danish biotech Zealand Pharma. It has a market value of just $3bn, less than 1 per cent that of Novo Nordisk. Like its compatriot, its share price has doubled over the past 14 months....
...By comparison, obesity drugs developer Novo Nordisk trades on 33.6 times. Roche is struggling to convince investors that it can boost its research productivity after high profile setbacks in 2022....
...Although AstraZeneca is in the race for a treatment, it is far behind the sector’s leaders Eli Lilly and Novo Nordisk....
...I devoured your article on Novo Nordisk “Anti-obesity drugs lift ambitions of world’s largest charitable foundation” (Report, December 30)....
...The crunchy acronym was coined by Goldman Sachs for pharma companies GSK and Roche, Dutch chip company ASML, Switzerland’s Nestlé and Novartis, Danish drugmaker Novo Nordisk, France’s L’Oréal and LVMH, the...
International Edition